Oxford Biomedica plc (LON:OXB - Get Free Report) insider Heather Preston purchased 11,389 shares of the stock in a transaction on Tuesday, June 17th. The stock was acquired at an average price of GBX 324 ($4.36) per share, with a total value of £36,900.36 ($49,623.94).
Oxford Biomedica Stock Up 2.4%
OXB stock traded up GBX 7.50 ($0.10) during mid-day trading on Friday, hitting GBX 321 ($4.32). 324,311 shares of the company were exchanged, compared to its average volume of 253,613. The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35. Oxford Biomedica plc has a 1-year low of GBX 232.50 ($3.13) and a 1-year high of GBX 455 ($6.12). The firm's 50 day simple moving average is GBX 309.10 and its 200 day simple moving average is GBX 346.87. The firm has a market cap of £341.23 million, a P/E ratio of -2.38 and a beta of 1.09.
Oxford Biomedica (LON:OXB - Get Free Report) last issued its quarterly earnings data on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.56)) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. On average, sell-side analysts predict that Oxford Biomedica plc will post -31.0799998 EPS for the current fiscal year.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Recommended Stories
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
